Nano-X pulls guidance, pivots to CapEx partnerships — but cash runway tightens

The imaging pioneer bets on distributors and RadNet visibility while restructuring Korea and facing a going-concern question.

NNOX · Earnings Call · 2026-06-25

A strategy pivot under cash pressure

Nano-X Imaging (NNOX) entered 2026 with a $35 million revenue target, but the first quarter results forced a recalibration. Management “no longer expect[s] to achieve the revenue target previously announced for 2026” — Erez Meltzer, Chief Executive Officer and Acting Chairman · 2026-06-25, and more consequential for investors, they will stop providing annual revenue guidance altogether. The reasoning: revenue recognition depends on site readiness, regulatory processes, and partner execution — factors largely outside the company's control. revenue guidance has been replaced by an emphasis on operational milestones: deployments, activations, and utilization. The strategic pivot is toward a CapEx-driven commercial model via partnerships. The company has signed “signed agreements for approximately 360 units with business partners over the next two to three years” — Erez Meltzer, Chief Executive Officer and Acting Chairman · 2026-06-25, with a major distributor expecting 60 units this year alone. These commercial agreements are meant to broaden coverage without expanding the direct sales force. The flagship reference site is RadNet, the largest outpatient imaging operator in the U.S., where the Nanox.ARC is now in commercial use.

Restructuring and the Korean question

Cost discipline is central. The company initiated a restructuring of its South Korean operations, with management evaluating "a broader restructuring that originally contemplated a potential sale of South Korean operations and related assets, or an orderly wind-down." South Korean operations have become a drag; the plant was built during COVID when semiconductors were scarce, and now the company has a cheaper supply. A restructuring plan is already being implemented, and the CFO expects operating expenses to decline sequentially. As Erez Meltzer put it: “The answer is yes. The reduction in Korean operations and cost savings in other areas... should result in a reduction in the burn rate.” — Erez Meltzer, Chief Executive Officer and Acting Chairman · 2026-06-25 But the balance sheet is stretched. Cash fell to $44.2 million from $60 million in the quarter, and operating cash burn was $14 million. Management says that raises

substantial doubt as to the company's ability to continue as a going concern
Erez Meltzer, Chief Executive Officer and Acting Chairman · 2026-06-25

. They are seeking additional capital, which may dilute shareholders.

AI and Health IT: the bright spot

Despite the hardware challenges, the AI and software segment is showing promise. The company's Health IT business, acquired with VasoHealthcare, contributed $0.9 million in revenue, and the company sees high margins. The AI business is targeting breakeven, with management now suggesting early 2027. The teleradiology business continues to grow, with a few hundred customers and rising MRI/CT volumes. The Nano X Imaging Network is pursuing higher-reimbursement segments like workers' comp and concierge medicine. The prior quarter's guidance had promised a second-half ramp: “I think that you will see most of it in the second half -- towards the second half of 2026” — Ran Daniel, Chief Financial Officer · 2026-04-20. That promise has now been walked back. The company maintains confidence in the long-term opportunity, but the market must weigh the cash runway against the potential of its pipeline.

What changed, and why it matters

The change here is not in the technology — the ARC and AI products are advancing — but in the go-to-market timeline and financial strategy. The company is trading top-line guidance for a more honest disclosure of operational metrics, a move that signals both maturity and vulnerability. The withdrawal of guidance, coupled with the going-concern language, makes this a high-risk story. If the partnerships convert to sales and the cost cuts hold, the pivot could work; if not, the company may need to raise capital at dilutive levels. The market will be watching the next few quarters for evidence of deployment numbers and scan volume growth.